Effective design of barrier enclosure to contain aerosol emissions from COVID-19 patients

Dan Daniel; Marcus Lin; Irvan Luhung; Tony Lui; Anton Sadovoy; Xueqi Koh; Anqi Sng; Tuan Tran; Stephan C. Schuster; Xian Jun Loh; Oo Schwe Thet; Chee Keat Tan

doi:10.1101/2020.12.22.20246868

Abstract

Facing shortages of personal protective equipment, some clinicians have advocated the use of barrier enclosures (typically mounted over the head, with and without suction) to contain aerosol emissions from coronavirus disease 2019 (COVID-19) patients. There is however little evidence for its usefulness. To test the effectiveness of such a device, we built a manikin that can expire micron-sized aerosols at flow rates close to physiological conditions. We then placed the manikin inside the enclosure and used a laser sheet to visualize the aerosol leaking out. We show that with sufficient suction, it is possible to effectively contain aerosol from the manikin even at high flow rates (up to 60 L min⁻¹) of oxygen, reducing aerosol exposure outside the enclosure by 99%. In contrast, a passive barrier without suction only reduces aerosol exposure by 60%.

Competing Interest Statement

Ngee Ann Polytechnic and Ng Teng Fong general Hospital have filed a patent submission for the barrier enclosure design.

Funding Statement

We are grateful to the Agency for Science, Technology and Research for providing financial support under A*CRUSE funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB exempt

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

↵† lohxj{at}imre.a-star.edu.sg
↵‡ thet_oo_shwe{at}np.edu.sg
↵§ chee_keat_tan{at}nuhs.edu.sg
Change the structure of the paper. Extra information on methods.

Data Availability

Data will be made available upon reasonable request.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.